The Gut-Brain Axis & Peptides

The gut-brain axis refers to the bidirectional communication network between the gastrointestinal tract and the central nervous system. This is not a metaphor — it is a physical signaling system involving the vagus nerve, the enteric nervous system (ENS), the hypothalamic-pituitary-adrenal (HPA) axis, immune mediators, microbial metabolites, and a diverse array of peptide hormones and neuropeptides.

The gut contains over 500 million neurons (the ENS), produces more than 20 identified signaling peptides, and houses approximately 70% of the body's immune cells. It is, functionally, a neuroendocrine organ — and its communication with the brain shapes mood, appetite, stress resilience, inflammation, and even cognitive function.

Vagus nerve: the primary highway

The vagus nerve (cranial nerve X) is the principal neural conduit of the gut-brain axis. It contains approximately 80% afferent (gut-to-brain) fibers and 20% efferent (brain-to-gut) fibers — the gut sends far more information to the brain than it receives.

Vagal afferent neurons have their cell bodies in the nodose ganglion and project to the nucleus tractus solitarius (NTS) in the brainstem. From the NTS, signals propagate to the hypothalamus, amygdala, and insular cortex — brain regions controlling appetite, emotion, and interoception.

Vagal afferents express receptors for numerous gut peptides: GLP-1, CCK, PYY, ghrelin, and serotonin (5-HT3). When these peptides are released by enteroendocrine cells in response to nutrients, they activate vagal afferents that relay satiety, nausea, or reward signals to the brain. Vagotomy (surgical cutting of the vagus) abolishes many of these gut-brain peptide signals and is associated with altered feeding behavior and mood.

Key gut-brain peptides

GLP-1 and central appetite regulation

GLP-1 (glucagon-like peptide-1) is secreted by intestinal L-cells in response to nutrient ingestion. Beyond its peripheral incretin effects (insulin secretion, glucagon suppression, gastric slowing), GLP-1 has direct central nervous system actions:

• GLP-1 receptors are expressed in the NTS, hypothalamus (arcuate and paraventricular nuclei), hippocampus, and mesolimbic reward circuits
• Peripheral GLP-1 activates vagal afferents projecting to the NTS
• Central GLP-1 signaling suppresses appetite, reduces food reward, and may improve cognitive function
• Hindbrain GLP-1 neurons in the NTS project to hypothalamic feeding centers

GLP-1 receptor agonists (semaglutide, liraglutide) produce their weight loss effects through both peripheral metabolic actions and central appetite suppression. The central effects include reduced food craving, decreased alcohol intake (observed in clinical studies), and modulation of reward circuitry — explaining why these drugs affect food behavior beyond simple satiety.

Cholecystokinin (CCK)

CCK is released by I-cells in the duodenum in response to fat and protein. It activates CCK-A receptors on vagal afferents, producing acute satiety. CCK was one of the first gut peptides identified as a satiety signal (1973). It also stimulates gallbladder contraction, pancreatic enzyme secretion, and has central effects on anxiety and panic (CCK-B receptor activation in the brain is anxiogenic — CCK-4 injection reliably provokes panic attacks in humans, a useful experimental model).

Neuropeptide Y (NPY) and Peptide YY (PYY)

NPY is one of the most abundant neuropeptides in the brain and a potent orexigenic (appetite-stimulating) signal. Hypothalamic NPY neurons in the arcuate nucleus are activated by fasting and ghrelin and suppressed by leptin and insulin. NPY also modulates anxiety, stress resilience, and sympathetic nervous system activity — it has anxiolytic effects, and higher NPY levels are associated with stress resilience in military personnel studies.

PYY (peptide YY) is released by distal intestinal L-cells after meals, particularly in response to fat. PYY3-36 (the active circulating form) acts on Y2 receptors in the arcuate nucleus to inhibit NPY neurons and suppress appetite. It represents the "ileal brake" — a feedback signal from the distal gut that slows transit and reduces intake.

Ghrelin

The only known orexigenic gut hormone. Produced primarily by gastric fundic cells, ghrelin rises before meals and falls after eating. It activates GHS-R1a receptors on vagal afferents and hypothalamic NPY/AgRP neurons, stimulating appetite. Ghrelin also promotes GH secretion and has emerging roles in stress-induced eating and food reward.

BPC-157 and gut-brain mechanisms

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a sequence in human gastric juice. Its proposed gut-brain mechanisms span multiple systems:

• Vagus nerve modulation — BPC-157 has been reported to counteract vagotomy effects in preclinical models, suggesting interaction with vagal signaling pathways
• Dopamine system — preclinical studies show BPC-157 modulates dopamine turnover, protecting against both dopamine agonist and antagonist-induced behavioral disturbances
• Nitric oxide system — BPC-157 interacts with the NO system, which is a key mediator of gut-brain communication and gastrointestinal motility
• GI cytoprotection — promotes gastric and intestinal mucosal healing, which may indirectly support gut-brain axis integrity by maintaining barrier function

It is important to note that BPC-157 research is predominantly preclinical (animal models). Human clinical data is limited, and the exact molecular target and receptor have not been definitively identified.

KPV and gut inflammation

KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the anti-inflammatory properties of alpha-MSH without its melanogenic effects. In preclinical colitis models, KPV reduces intestinal inflammation by inhibiting NF-kB activation in colonocytes and immune cells. Given the gut-brain axis framework, reducing gut inflammation can attenuate inflammatory signaling to the brain — intestinal inflammation drives vagal afferent activation that promotes sickness behavior, fatigue, and mood disturbance.

The microbiome dimension

Gut microbiota are integral to gut-brain axis signaling. Bacteria produce neuroactive metabolites (short-chain fatty acids, tryptophan metabolites including serotonin precursors, GABA) and influence enteroendocrine cell peptide secretion. Microbial metabolites modulate vagal afferent activity and intestinal barrier permeability. Dysbiosis (altered microbial composition) is associated with altered gut peptide profiles and has been linked to depression, anxiety, and irritable bowel syndrome.

Peptide interventions that restore gut mucosal integrity or modulate enteroendocrine cell function may therefore influence brain function not only through direct peptide signaling but also by shaping the microbial-neuroendocrine interface.

Clinical implications

The gut-brain axis framework explains several clinical observations: why GLP-1 agonists reduce appetite through central mechanisms, why inflammatory bowel disease is comorbid with depression and anxiety, why vagus nerve stimulation is FDA-approved for treatment-resistant depression, and why the gut peptide environment after bariatric surgery (altered GLP-1, PYY, ghrelin profiles) contributes to metabolic improvements beyond mechanical restriction. Understanding peptide-mediated gut-brain communication is increasingly central to both gastroenterology and neuroscience.